(95% CI: 12.49-14.65) for the platinum-sensitive recurrence group, while the median overall survival (OS) was not reached in either group.Conclusions:This pioneering multicentric study sheds light on the landscape of primary platinum-resistant ovarian cancer in India, revealing critical gaps in ...
Platinum is a key component of ovarian cancer systemic therapy. However, most patients will eventually face a recurrence, leading to chemotherapy resistance, especially against platinum. For individuals with platinum-resistant ovarian cancer (PROC), treatment options are limited, and their survival prospe...
Platinum is a key component of ovarian cancer systemic therapy. However, most patients will eventually face a recurrence, leading to chemotherapy resistance, especially against platinum. For individuals with platinum-resistant ovarian cancer (PROC), treatment options are limited, and their survival prospe...
The optimal duration of therapy for women with platinum-resistant ovarian cancer who respond to second-line treatment programs remains undefined. A patient with well-documented platinum-resistant ovarian cancer who responded to single-agent paclitaxel (175 mg/m2 over 3 hours q 28-35 days) was cont...
as well as platinum resistant versus sensitive human ovarian cancer patient samples. The prognostic significance of the different proteomics-identified marker proteins in prognosis prediction on survival as well as their correlative association and influence on immune cell infiltration was determined by publi...
In Study 19, maintenance monotherapy with olaparib significantly prolonged progression-free survival vs placebo in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer. Study 19 was a randomised, placebo-controlled, Phase II trial
reported "Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy", on Eur J Cancer (1). Via the data from chemotherapy-only arm in AURELIA and randomized cases in CARTAXHY trial as training cohort, Dr....
Emerging Concepts-Advanced Ovarian, Fallopian, Peritoneal, and Cervical Cancers: Episode3 Video July 2, 2015 For High-Definition, Click The phase III GOG-0213 clinical trial evaluated paclitaxel and carboplatin with or without bevacizumab in women with platinum-sensitive ovarian cancer. Chemotherapy was...
The objective was to determine the response rate to platinum retreatment of "platinum-resistant" ovarian cancer after intervening nonplatinum therapy. We retrospectively identified 30 patients with platinum-resistant ovarian cancer who received nonplatinum chemotherapy for recurrent epithelial ovarian cancer pr...
The median survival of patients with platinum sensitive recurrent ovarian cancer is estimated to be 2 years, but it can range from only a few months to more than a decade. Patients who relapse within 6 months of completing first-line therapy have been classified as being “platinum resistant”...